Union for International Cancer Control : TNM Classification System. 7th edition, 2009
Sonpave G : PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial carcinoma. New Engl J Med, 2017 (Epub ahead of print)
Rosenberg JE, Hoffman-Censits J, Powles T, et al : Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial. Lancet 387: 1909-1920, 2016
Massard C, Gordon MS, Sharma S, et al : Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 34: 3119-3125, 2016